520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants

BACKGROUND: BRII-196 and BRII-198 are human monoclonal antibodies (mAb) with an extended half-life targeting distinct epitopes of the spike protein on SARS-CoV-2. Mutations in these epitope regions are continuously emerging, potentially conferring resistance to COVID-19 therapeutics in development....

Descripción completa

Detalles Bibliográficos
Autores principales: Margolis, David A, Zhang, Fujie, Hao, Xiaohua, Li, Yanyan, Wang, Mingming, Li, Chunming, Zhang, Yao, Ma, Ji, Ji, Yun, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644370/
http://dx.doi.org/10.1093/ofid/ofab466.719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644370/
http://dx.doi.org/10.1093/ofid/ofab466.719

Ejemplares similares